Danaher Corporation
DHR
$194.98
-0.61%
Danaher Corporation is a global science and technology innovator, primarily manufacturing scientific instruments, consumables, and diagnostics for the life sciences and diagnostics industries. As a market leader in these sectors, Danaher is known for its Danaher Business System (DBS) and a portfolio of iconic brands like Cytiva and Beckman Coulter. The current investor narrative centers on the company's post-Veralto divestiture focus, its recent acquisition of Masimo, and a temporary shipment delay in its biotech segment that caused a sharp but potentially overdone stock drop, creating a debated buying opportunity.…
DHR
Danaher Corporation
$194.98
Related headlines
Investment Opinion: Should I buy DHR Today?
Based on the analysis, DHR is rated a Buy. The consensus Strong Buy with an average target of $227.96 implies 16.9% upside, and the forward PE of 20.99x is in line with the industry, suggesting the stock is reasonably valued on forward earnings. The company's high gross margin of 60.34% and net margin of 17.29% demonstrate strong profitability, and recurring revenue provides stability. However, the trailing PE of 45.15x is a concern, and the recent shipment delays add uncertainty. This Buy rating is contingent on the delays being temporary and the Masimo integration proceeding smoothly. If the biotech segment fails to recover or integration issues arise, the rating would be downgraded to Hold. Overall, DHR appears fairly valued relative to its growth prospects, with a slight premium on trailing earnings but reasonable on forward basis.
Sign up to view all
DHR 12-Month Price Forecast
The AI assessment is cautiously bullish, as the forward valuation is reasonable and the company's margins are strong. The key risk is the biotech shipment delays, which could be temporary but are not yet resolved. If the delays persist, the stance would be downgraded to neutral. Conversely, if the company reports strong Q2 earnings and the delays are resolved, the stance would be upgraded to high confidence bullish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $227.96 and implied upside of +16.9% versus the current price.
Average Target
$227.96
0 analysts
Implied Upside
+16.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$195 - $310
Analyst target range
Danaher is covered by 23 analysts, with a consensus recommendation of 'Strong Buy' and a mean recommendation score of 1.5. The average target price is $227.96, implying an upside of 16.9% from the current price of $194.98. The target range is wide, from a low of $195.00 to a high of $310.00, indicating significant uncertainty about the company's future performance. The high target suggests expectations of a strong recovery and multiple expansion, while the low target reflects concerns about ongoing challenges in the biotech segment and integration risks from the Masimo acquisition. Recent ratings actions show a mix of affirmations and one downgrade (Citigroup from Buy to Neutral), but the overall sentiment remains bullish.
Bulls vs Bears: DHR Investment Factors
Danaher presents a mixed picture: strong fundamentals with high margins and a stable recurring revenue base, but a premium valuation and recent operational hiccups. The bull case rests on the forward PE being in line with industry and analyst optimism, while the bear case highlights the trailing PE premium and negative momentum. Currently, the bull side has stronger evidence given the consensus Strong Buy and the potential for earnings recovery, but the key tension is whether the biotech shipment delays are truly temporary or signal deeper demand issues. If the delays resolve quickly, the stock could re-rate; if not, the premium valuation could compress further.
Bullish
- Strong Buy consensus with 16.9% upside: 23 analysts rate DHR a Strong Buy with a mean score of 1.5 and an average target of $227.96, implying 16.9% upside from the current $194.98. The high target of $310 suggests significant recovery potential if the biotech segment normalizes.
- High margins and profitability: Q1 2026 gross margin was 60.34% and net margin 17.29%, both above industry averages for medical diagnostics. This demonstrates pricing power and operational efficiency, supporting earnings growth.
- Recurring revenue provides stability: Recurring revenue of $5.031 billion accounts for ~84.5% of total Q1 revenue, providing a stable base that cushions against cyclical downturns and supports consistent cash flows.
- Forward PE in line with industry: Forward PE of 20.99x is roughly in line with the industry average of 22x, suggesting the market expects earnings to normalize. This implies the stock is not overvalued on forward earnings.
Bearish
- Trailing PE at 105% premium: Trailing PE of 45.15x is more than double the industry average of 22x, indicating the market is paying a premium for current earnings. This leaves little room for disappointment.
- Sharp stock decline and negative momentum: The stock is down 11.06% over the past year and 10.92% over six months, with a max drawdown of -33.11%. The recent 12% weekly drop on shipment delays shows vulnerability to negative news.
- Biotech segment shipment delays: Temporary shipment delays in the biotech segment caused a sharp stock drop, highlighting operational risks and potential revenue timing issues that could persist.
- Masimo acquisition integration risks: The Masimo deal is seen as conservative rather than transformative, and investors question the valuation. Integration challenges could distract management and dilute focus.
DHR Technical Analysis
Danaher's stock has been in a pronounced downtrend over the past year, with a 1-year price change of -11.06% and a 6-month change of -10.92%. The current price of $194.98 sits at 80.3% of its 52-week range (between $160.93 low and $242.80 high), indicating the stock is closer to the lower end, reflecting a bearish sentiment and potential value territory. The stock's beta of 0.823 suggests it is less volatile than the market, which may offer some downside protection in turbulent times.
Beta
0.82
0.82x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
-1.1%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | +0.3% |
| 3m | +11.3% | +4.0% |
| 6m | -10.9% | +8.3% |
| 1y | -1.1% | +20.2% |
| ytd | -15.4% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows modest growth, with the most recent quarter (Q1 2026) reporting revenue of $5.951 billion, a 3.66% YoY increase. This follows a pattern of sequential growth from $5.936 billion in Q2 2025 to $6.838 billion in Q4 2025, indicating a steady but slow recovery. The company's recurring revenue segment, which accounts for $5.031 billion of total revenue, provides a stable base, while non-recurring revenue of $0.92 billion adds volatility. This growth is supported by strong profitability, with a gross margin of 60.34% and a net margin of 17.29% in Q1 2026, both above industry averages for medical diagnostics.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+3.7%
YoY Comparison
Gross Margin
60.3%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Given Danaher's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 45.15x, while the forward PE is 20.99x, indicating the market expects significant earnings growth. This gap is substantial, suggesting that analysts anticipate a strong recovery in earnings, possibly driven by the Masimo acquisition and operational improvements. Compared to the industry average PE of 22x, Danaher's trailing PE is at a 105% premium, but its forward PE is in line with the industry, implying that the market is pricing in a return to normal profitability.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.35, which is manageable but not negligible, and a payout ratio of 24.3% indicating moderate dividend coverage. The company's net margin of 17.29% is solid, but the trailing PE of 45.15x implies high earnings expectations; any shortfall could lead to multiple compression. Free cash flow of $5.29 billion TTM provides a cushion, but the Masimo acquisition adds integration and financing risks. Revenue growth is modest at 3.66% YoY, and non-recurring revenue of $0.92 billion introduces volatility.
FAQ
Key risks include: 1) Operational risk from biotech shipment delays, which could persist and hurt revenue. 2) Integration risk from the Masimo acquisition, which may not deliver expected synergies. 3) Valuation risk from the high trailing PE, which could compress if growth disappoints. 4) Macro risk from a slowdown in life sciences spending. The most severe risk is a prolonged delay leading to a -17.5% drop to the 52-week low.
The 12-month forecast is bullish with a base case target of $227.96 (16.9% upside), a bull case of $310 (59% upside), and a bear case of $161 (17.5% downside). The base case has a 50% probability, assuming the biotech delays resolve and the Masimo acquisition performs as expected. The bull case (30%) requires strong recovery, while the bear case (20%) assumes persistent challenges.
DHR's trailing PE of 45.15x is 105% above the industry average of 22x, suggesting overvaluation on current earnings. However, the forward PE of 20.99x is in line with the industry, implying the market expects significant earnings growth. The stock is fairly valued on forward earnings but overvalued on trailing earnings. The market is pricing in a recovery in profitability, which may or may not materialize.
DHR is a good buy for long-term investors given its strong margins, recurring revenue, and analyst upside of 16.9%. However, the trailing PE of 45.15x is high, and the recent shipment delays add risk. The stock is a good buy if you believe the delays are temporary and the Masimo acquisition will add value. For short-term traders, the volatility may offer opportunities, but the risk is elevated. Overall, it's a buy for those with a 3-5 year horizon.
DHR is more suitable for long-term investment due to its stable recurring revenue, high margins, and strong market position. The stock's beta of 0.823 indicates lower volatility, but it has underperformed recently. Short-term trading is possible given the volatility from news events, but the company's fundamentals support a 3-5 year holding period. The dividend yield of 0.54% is modest, but the payout ratio of 24.3% suggests room for growth.